Jan 3, 2019 • 7:00am EST

Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored

Clinical Study of SYN-010, for the Treatment of IBS-C ROCKVILLE, Md., Jan. 3, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that the first two patients have been enrolled in SYN-010's Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin lactone designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irrita...